Editorial: citrullination, and carbamylation, and malondialdehyde-acetaldehyde! Oh my! Entering the forest of autoantigen modifications in rheumatoid arthritis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Assessment of anti-malondialdehyde-acetaldehyde antibody frequencies in rheumatoid arthritis with new data from two independent cohorts, meta-analysis, and meta-regression.Arthritis research & therapy · 2023
   Pooled it
2. Pomegranate extract alleviates disease activity and some blood biomarkers of inflammation and oxidative stress in Rheumatoid Arthritis patients.European journal of clinical nutrition · 2017
   Trial
3. Joint Tissues: Convergence and Divergence of the Pathogenetic Mechanisms of Rheumatoid Arthritis and Osteoarthritis.International journal of molecular sciences · 2025
   Review
4. Leaky gut, circulating immune complexes, arthralgia, and arthritis in IBD: coincidence or inevitability?Frontiers in immunology · 2024
   Article
5. Oxidative Stress as a Regulatory Checkpoint in the Production of Antiphospholipid Autoantibodies: The Protective Role of NRF2 Pathway.Biomolecules · 2023
   Review
6. Different Clinical Relevance of Anti-Citrullinated Protein Antibodies in RA Patients.Doklady. Biochemistry and biophysics · 2023
   Article
7. Redox-Mediated Carbamylation As a Hapten Model Applied to the Origin of Antibodies to Modified Proteins in Rheumatoid Arthritis.Antioxidants & redox signaling · 2022
   Review
8. Host and bacterial factors linking periodontitis and rheumatoid arthritis.Frontiers in immunology · 2022
   Review
9. Localisation of citrullinated and carbamylated proteins in inflamed gingival tissues from rheumatoid arthritis patients.Clinical oral investigations · 2021
   Article
10. Current view on the pathogenic role of anti-citrullinated protein antibodies in rheumatoid arthritis.RMD open · 2021
    Review
11. Immunogenic and inflammatory responses to citrullinated proteins are enhanced following modification with malondialdehyde-acetaldehyde adducts.International immunopharmacology · 2020
    Article
12. Disordered Antigens and Epitope Overlap Between Anti-Citrullinated Protein Antibodies and Rheumatoid Factor in Rheumatoid Arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2020
    Article
13. Obstructive lung diseases and risk of rheumatoid arthritis.Expert review of clinical immunology · 2020
    Review
14. Individuals at risk of seropositive rheumatoid arthritis: the evolving story.Journal of internal medicine · 2019
    Review
15. Rheumatoid Arthritis-Associated Mechanisms ofJournal of clinical medicine · 2019
    Review
16. Antibody-dependent and -independent mechanisms of inflammatory arthritis.JCI insight · 2019
    Review
17. Diagnostic performance of a new vimentin-derived ACPA (CCP high sensitive) in patients with rheumatoid arthritis.Immunologic research · 2016
    Article

Corrections and comments

• Comment on
  Malondialdehyde-acetaldehyde adducts and anti-malondialdehyde-acetaldehyde antibodies in rheumatoid arthritis.2015

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as